# Neoadjuvant Chemoradiation With Bevacizumab for Chinese Rectal Cancer Patients

> **NCT01554059** · PHASE2 · COMPLETED · sponsor: **Sixth Affiliated Hospital, Sun Yat-sen University** · enrollment: 25 (actual)

## Conditions studied

- Rectal Adenocarcinoma

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Oxaliplatin
- **DRUG:** 5-FU
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT01554059
- **Lead sponsor:** Sixth Affiliated Hospital, Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2013-05
- **Final completion:** 2014-08
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2014-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01554059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01554059, "Neoadjuvant Chemoradiation With Bevacizumab for Chinese Rectal Cancer Patients". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01554059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*